P-Bromoanisole

Shouguang Fukang Pharmaceutical, established in 1993, manufactures active pharmaceutical ingredients and intermediates for proton-pump inhibitors and antipsychotics, including lansoprazole, its key intermediate 2-chloromethyl-3,4-dimethoxypyridinium chloride, clozapine, itraconazole, and trimethoxybenzene/trimethoxytoluene derivatives, alongside sulfonamide and hormone-related compounds. Holding international approvals and offering CMO and CDMO contract manufacturing with OEM and own-brand production, the company arranges payment terms case by case and serves customers across North America, Europe, Asia, the Middle East, and Africa.